Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937813 | 0.92 | PPARA (0.56) | PPARACTSKPPARGACECTSS | |
| SCHEMBL29396254 | 0.92 | PPARA (0.56) | PPARACTSKPPARGACECTSS | |
| Lysine SCHEMBL1024011 | 0.86 | PPARA (0.47) | PPARACTSKMAPTKLK7KLK5 | |
| SCHEMBL31300256 | 0.85 | CTSK (0.52) | PPARACTSKCTSSSYKMAPT | |
| SCHEMBL1021830 | 0.84 | CTSK (0.50) | PPARACTSKPPARGCTSSSYK | |
| SCHEMBL918814 | 0.84 | MAPT (0.52) | CTSKSYKMAPTKLK7KLK5 | |
| SCHEMBL1021939 | 0.84 | MAPT (0.52) | CTSKSYKMAPTKLK7KLK5 | |
| SCHEMBL3820597 | 0.83 | KLK7 (0.50) | PPARACTSKCTSSSYKMAPT | |
| SCHEMBL375888 | 0.83 | KLK7 (0.50) | PPARACTSKCTSSSYKMAPT | |
| SCHEMBL3824366 | 0.83 | MAPT (0.56) | SYKMAPTKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035851-A1 | Modulators Of NOD1 Signaling | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-02-05 | — | — | US | disclosed |
| US-20060258580-A1 | Such as N-acyl/myristoyl-gamma-glucose-diaminopimelic acid dipeptides; for activation of nuclear factor kappa beta; for treatment of inflammatory diseases such as Crohn's disease and asthma; drug screening | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258580-A1 | Such as N-acyl/myristoyl-gamma-glucose-diaminopimelic acid dipeptides; for activation of nuclear factor kappa beta; for treatment of inflammatory diseases such as Crohn's disease and asthma; drug screening | NOD2, NOD1, TLR1 | PPARA 1803/4885CTSK 4198/4885PPARG 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.